Pharma Focus Asia

Armas and Micro Labs Announce Collaboration To Launch Generic Injectables to U.S. Market

Wednesday, May 29, 2019

Armas Pharmaceuticals Inc. and Micro Labs USA, Inc. have announced today, the forming of a strategic collaboration to bring select multisource injectable products to the U.S. market. The first product, Diphenhydramine Injection 50mg/1mL, is slated to be launched in May. Diphenhydramine has been seen on the FDA Drug Shortage list since September of 2018. Additional product launches are set for the second quarter of 2019. The market size of these products total $100 million annually, according to IMS data.

"Armas Pharmaceuticals is excited to partner with Micro Labs as we look to expand our product line across multiple therapeutic classes," said John Niemi, President and CEO of Armas. "Our first launch with Micro Labs, Diphenhydramine Injection 50mg/1mL, is a medicinal drug used widely in the healthcare space. It is our aim to make this product available at affordable pricing to patients in need of the same. This medication reinforces our ultimate goal to bring high quality, affordable drugs that are needed in the U.S. market."

Ashok Jain, Director of Micro Labs USA, Inc. said, "Micro and Armas have been working together on various ideas and projects. We are proud to be associated with Armas and we truly value the rich experience and understanding of the US healthcare sector they bring to the partnership."

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024